<DOC>
	<DOCNO>NCT00410449</DOCNO>
	<brief_summary>Complications hemodialysis access frequent single reason hospitalization among patient End Stage Renal Disease ( ESRD ) . Uremia , particularly uremia patient diabetes , state increase oxidative stress . The central hypothesis test project oxidative stress major ( modifiable ) trigger vascular access complication . We hope slow reduce rate stenosis , thrombosis access complication give Vitamin E supplementation patient treat hemodialysis .</brief_summary>
	<brief_title>Oxidative Stress Hemodialysis Access Failure</brief_title>
	<detailed_description>Patients continue usual treatment hemodialysis three time per week . This double-blinded placebo control trial . Patients take either Vitamin E 400 IU bid placebo . An initial evaluation access patency perform baseline blood drawn start Vitamin E. Every 3 month followup evaluation blood drawn oxidative stress marker , test vascular access patency . The study close new participant , vitamin E placebo stop , data analysis perform 2003 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>Adults , end stage renal disease treat hemodialysis , patent hemodialysis vascular access ( graft fistula ) Temporary catheter dialysis access , inability compliant study medication</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>End stage renal disease treat hemodialysis</keyword>
	<keyword>Hemodialysis vascular access patency</keyword>
	<keyword>Vitamin E</keyword>
	<keyword>oxidative marker</keyword>
	<keyword>pentosidine</keyword>
	<keyword>hydroxynonenal</keyword>
	<keyword>levuglandin</keyword>
</DOC>